We’re lucky at End­points News.

Read­er en­gage­ment is the high­est we’ve ever seen as we ap­proach 80,000 dai­ly email sub­scribers — with over 20% of them un­der a paid plan. Busi­ness op­er­a­tions are strong, with our team of 17 de­ployed at home of­fices across the US, Eu­rope, and Asia be­fore it be­came manda­to­ry. And we can sell ad­ver­tis­ing to clients who need to reach a hy­per-fo­cused au­di­ence. It’s a way of reach­ing out, with­out touch­ing, that has be­come in­creas­ing­ly trendy. The vir­tu­al na­ture of our busi­ness gives us a few crit­i­cal ad­van­tages in re­spond­ing to the cri­sis.

There are chal­lenges, of course.

Live events ac­count for a third of our rev­enues — or used to, at least. Con­nect­ing the bio­phar­ma world is a vi­tal part of our mis­sion, and there’s no re­al sub­sti­tute for mak­ing new per­son­al con­nec­tions at con­fer­ences.

So un­til we’re able to meet in close quar­ters again — stretch­ing well in­to 2021 — all End­points events will be vir­tu­al. We’re start­ing with an ag­gres­sive slate of vir­tu­al Zoom pan­els fea­tur­ing the in­dus­try’s top lead­ers. We’ll have more on that soon. And the team is look­ing at new and in­no­v­a­tive ways at de­liv­er­ing these events, be­yond the stan­dard video pan­els. There’s a huge op­por­tu­ni­ty to reimag­ine on­line con­fer­ences and the val­ue they bring to both at­ten­dees and spon­sors.

To be sure, the bio­phar­ma in­dus­try it­self is demon­strat­ing some re­al re­silience in the cri­sis. That’s im­por­tant. Bio­phar­ma will be back, al­tered — cer­tain­ly — but more fo­cused on big things than ever be­fore.

We’re look­ing for­ward to writ­ing about that.

While we’ve been fo­cused on cov­er­ing the out­break and its im­pact on the in­dus­try — our spe­cial niche — we’ve put few­er sto­ries be­hind the pay­wall. That will change soon, and we need your sup­port now more than ever.

Up­grad­ing to a pre­mi­um plan

The best way to sup­port End­points News is for your com­pa­ny to pur­chase an En­ter­prise sub­scrip­tion. It’s a trans­par­ent­ly priced, flat-rate plan that cov­ers all em­ploy­ees at your or­ga­ni­za­tion, start­ing at $1,000/year. That grants ac­cess to our en­tire pay­wall li­brary and con­fers a li­cense for your com­pa­ny to reprint and share our con­tent in­ter­nal­ly as you please.

In­di­vid­u­als can sign up for an In­sid­er plan, which is now $225/year. In ad­di­tion to the pay­wall li­brary, In­sid­ers can dis­able all ad­ver­tis­ing. If you want to read just the con­tent and noth­ing else, this is the plan for you.

We’ll con­tin­ue to of­fer the bulk of our sto­ries for free ac­cess. But any com­pa­ny or in­di­vid­ual look­ing for the com­plete pic­ture should get a paid sub­scrip­tion. The prices are af­ford­able, trans­par­ent, and pro­vide a ton of val­ue.

Most im­por­tant­ly, with both plans, you’re di­rect­ly sup­port­ing the fu­ture de­vel­op­ment of End­points News.

It’s our paid sub­scribers — who’ve been with us years — that put us in the dri­ver’s seat, in charge of our des­tiny, nav­i­gat­ing the big changes ahead for the me­dia busi­ness. With your sup­port, we’ll keep build­ing the staff through the tough times ahead.

For those of you who have a paid sub, thank you. For those of you get­ting one to­day, be sure that we have nev­er been more ap­pre­cia­tive of your sup­port for the in­de­pen­dent mis­sion we have carved out for our­selves as we boot­strapped this start­up.

You can sign up here. If you have spe­cial re­quests, you can open up a chat with our sup­port team at this page.

And if you need to reach our bio­phar­ma au­di­ence with a pro­mo­tion­al cam­paign, please drop a line to our rev­enue chief, Mike Peck (mike@end­pointsnews.com). We are open for (vir­tu­al) busi­ness 24/7.

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

US regulators cleared an ultra-rare drug from Pharming Group, by way of Novartis, on Friday afternoon.

The Dutch biotech said the FDA greenlit leniolisib for an immunodeficiency disease known as activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome, or APDS. People 12 years and older can receive the oral drug, to be marketed as Joenja, beginning early next month, Pharming said, five days ahead of the decision deadline set by the FDA as part of a priority review.

A California judge will allow a plaintiff in a state court case to introduce expert testimony connecting a potential carcinogen in former blockbuster medicine Zantac to cancer.

The order was handed down on Thursday from state judge Evelio Grillo, who is now allowing both parties to introduce expert testimony in an upcoming trial after what’s known as a Sargon hearing, where a judge determines the admissibility of expert witnesses and expert opinions.